Table 1.

The effect of prednisolone/rituximab on the FVIII activity, anti-FVIII inhibitor and neutrophil counts in a patient with AHA in association with CNL

	Time after first treatment* (weeks)	FVIII activity (%)	Anti-FVIII inhibitor (BU/mL)	Absolute neutrophil count (ANC/μL)	P***
Before treatment	–	<1.0	190	25,943 ± 5,567**	–
After two doses of rituximab	4–8	2.0	4.9	16,393 ± 5,330	0.04
After two more doses of rituximab	10–11	from 5.0 to 28.0	1.2	7,689 ± 7,472	0.004
BM tested	11th	–	1.2	–#	–
Thereafter	12–16	from 28.0 to 6.0	0.2–0.1	11,850 ± 1,404	0.016
Relapse	20th	6.0	5.3	6,332	–
	22nd##	2.0	91.5	7,678

Notes:

^*Prednisolone and rituximab;

^**mean ± SD;

^***Student’s t-test (ANC compared with the prerituximab ANC);

^#the bone marrow was moderately cellular with an M/E ratio of 2.2.

^##treatment and response after relapse (see text).

Abbreviations: AHA, acquired hemophilia A; ANC, absolute neutrophil count; BM, bone marrow; BU, Bethesda unit; CNL, chronic neutrophilic leukemia; FVIII, coagulation factor VIII; M/E, myeloid:erythroid; SD, standard deviation.